Key Details
Price
$16.28Annual ROE
-31.55%Beta
1.30Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 26, 2009Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.
NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK CITY, NY / ACCESSWIRE / November 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
NEW YORK, NY / ACCESSWIRE / November 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
FAQ
- What is the primary business of Myriad Genetics?
- What is the ticker symbol for Myriad Genetics?
- Does Myriad Genetics pay dividends?
- What sector is Myriad Genetics in?
- What industry is Myriad Genetics in?
- What country is Myriad Genetics based in?
- When did Myriad Genetics go public?
- Is Myriad Genetics in the S&P 500?
- Is Myriad Genetics in the NASDAQ 100?
- Is Myriad Genetics in the Dow Jones?
- When was Myriad Genetics's last earnings report?
- When does Myriad Genetics report earnings?
- Should I buy Myriad Genetics stock now?